104 related articles for article (PubMed ID: 7545251)
21. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.
deVere White RW; Hackman RM; Soares SE; Beckett LA; Li Y; Sun B
Urology; 2004 Feb; 63(2):259-63. PubMed ID: 14972467
[TBL] [Abstract][Full Text] [Related]
22. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
25. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
26. Intermittent complete androgen blockade in metastatic prostate cancer.
Rambeaud JJ
Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
[TBL] [Abstract][Full Text] [Related]
27. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ
J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
[TBL] [Abstract][Full Text] [Related]
28. Innovative approaches to the hormonal treatment of advanced prostate cancer.
Trachtenberg J
Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790
[TBL] [Abstract][Full Text] [Related]
29. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
30. [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].
Pfitzenmaier J; Altwein JE
Aktuelle Urol; 2009 Mar; 40(2):100-8. PubMed ID: 19253209
[TBL] [Abstract][Full Text] [Related]
31. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
32. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
Spitz IM; Chertin B; Fridmans A; Farkas A; Belanger A; Hartman H; Labrie F
Prostate Cancer Prostatic Dis; 2009; 12(1):100-3. PubMed ID: 18574491
[TBL] [Abstract][Full Text] [Related]
33. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Cherrier MM; Rose AL; Higano C
J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
[TBL] [Abstract][Full Text] [Related]
34. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
35. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
36. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
Shulman MJ; Karam JA; Benaim EA
Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
[TBL] [Abstract][Full Text] [Related]
37. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Masue N; Hasegawa Y
Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
[TBL] [Abstract][Full Text] [Related]
38. Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate.
Akakura K; Akimoto S; Furuya Y; Ito H
Eur Urol; 1998; 33(6):567-71. PubMed ID: 9743699
[TBL] [Abstract][Full Text] [Related]
39. Maximal androgen blockade versus total androgen suppression.
Dumez H; Van Poppel H; Baert L; Paridaens R
Acta Urol Belg; 1997 Mar; 65(1):49-54. PubMed ID: 9175283
[TBL] [Abstract][Full Text] [Related]
40. [Preventive effect of chlormadinone acetate on flare-up phenomenon in advanced prostate cancer administered with a luteinizing hormone-releasing hormone analogue].
Sato N; Kotake T; Masai M; Sakai S; Ito H
Hinyokika Kiyo; 2000 Jan; 46(1):1-7. PubMed ID: 10723656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]